Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84) and Angiotensin II, published as a randomized controlled trial.

The researchers evaluated the effect of individual RAAS components on PTH using 4 interventions in humans without primary hyperaldosteronism.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with Parathyroid Hormone (PTH 1-84) could be set against what happens without it.

In the crossover set-up each of the participants took both Parathyroid Hormone (PTH 1-84) and the comparison in turn, acting as their own control.

A time span of 6 weeks appears in the methods.

What Was Measured

The researchers evaluated the effect of individual RAAS components on PTH using 4 interventions in humans without primary hyperaldosteronism.

PubMed files the paper under topics including Aldosterone, Angiotensin II, Antihypertensive Agents, Captopril, Diuretics, Hyperaldosteronism and Hypertension.

The authors tagged it with the keywords calcium, parathyroid hormone, renin-angiotensin system, spironolactone and vitamin D.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of Parathyroid Hormone (PTH 1-84) and Angiotensin II over 6 weeks.

The publication is from 2014 (Hypertension (Dallas, Tex. : 1979)), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page and the Angiotensin II compound page, all human trials.